ST. LOUIS, Oct. 2, 2024 /PRNewswire/ -- Ambetter Health, the marketplace health insurance offered by subsidiaries of Centene Corporation (NYSE: CNC), a leading healthcare enterprise committed to helping people live healthier lives, announced today it will expand its geographic footprint, adding 60 new counties across 10 states in 2025, which includes expansion into Iowa. Ambetter Health will be available in 29 states across the U.S.
In 2024, Ambetter Health remained the number one marketplace health insurance based on enrollment and market share, providing insurance to more than 4.4 million members.
"Our continued geographic and product expansion provides us with a unique opportunity to deliver comprehensive, affordable health insurance solutions to more members for the 2025 plan year," said Chief Executive Officer of Ambetter Health, Kevin Counihan. "This ensures even greater access to high quality health care in the communities we serve across the country."
In addition to providing coverage for all essential health benefits, including preventive and wellness services, maternity and newborn care, pediatric services, mental health services, hospitalizations, prescription drug coverage, and dental and vision in select states, Ambetter Health's 2025 offerings include:
The open enrollment period for the Health Insurance Marketplace runs Nov. 1, 2024, through January 2025. End dates will vary by state. For more information about Ambetter Health and its health coverage options, please visit www.ambetterhealth.com.
Ambetter Health is a health insurance offering that is available on the Health Insurance Marketplace, or exchange, established by the Affordable Care Act. It is one of the healthcare programs provided by Centene Corporation, a leading healthcare enterprise committed to helping people live healthier lives. Ambetter Health is made available through local health plans and covers a wide variety of healthcare services, including preventive and wellness services, maternity and newborn care, pediatric services, mental health and substance misuse services, prescription drug coverage and more. Statistical claims and the #1 Marketplace Insurance statement are in reference to national on-exchange marketplace membership and based on national Ambetter data in conjunction with findings from 2024 Rate Review data from CMS, 2024 State-Level Public Use File from CMS, state insurance regulatory filings, and public financial filings. This is a solicitation for insurance. For more information on health benefits and health insurance plans in your state, please visit the state specific link on AmbetterHealth.com.
*Discount valid only for in-store purchases of eligible Walgreens brand health and wellness products by current members eligible for the Ambetter Health discount program. Discount cannot be used online. For a full list of Walgreens brand health and wellness products, please visit Walgreens.com/SmartSavings. Offer not available on the following items: alcohol, charitable donations, dairy, home medical equipment and durable medical equipment products, items or services submitted to insurance for reimbursement or where otherwise limited by law, liquor departments, lottery tickets, magazines, money orders/transfers, newspapers, pharmacy items and services, phone/prepaid/gift cards, photo orders, prescriptions, Prescriptions Savings Club membership fee, pseudoephedrine or ephedrine products, stamps, tobacco and transportation passes. Walgreens reserves the right to discontinue the offer at its discretion.
Last Trade: | US$64.81 |
Daily Change: | 0.99 1.55 |
Daily Volume: | 4,953,508 |
Market Cap: | US$34.090B |
October 30, 2024 October 25, 2024 September 11, 2024 August 29, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB